SK Biopharmaceuticals has launched a joint venture, Mentis Care, Inc., with Eurofarma, a leading pharmaceutical company based in Brazil, to develop and commercialize an AI-powered epilepsy management platform. The announcement was made during a launch event held on October 20 in Toronto, Canada, marking SK Biopharmaceuticals’ strategic expansion into digital healthcare beyond its core drug development initiatives. Since 2018, SK Biopharmaceuticals has been building expertise in AI-driven electroencephalography (EEG) and wearable technologies focused on real-time seizure detection and monitoring. Mentis Care will leverage these capabilities to create an integrated digital platform that combines AI-powered seizure prediction, real-time monitoring, and clinical decision support tools to deliver personalized care for epilepsy patients. Headquartered in the MaRS Discovery District in Toronto—a major innovation hub for life sciences and healthcare—Mentis Care plans to grow its local team, strengthen academic and industry partnerships, and advance clinical validation of its AI algorithms. Eurofarma will lead the joint venture’s business strategy and AI data training, drawing on its deep presence in Latin America and growing footprint in North America and Africa. The collaboration builds on an existing partnership between the two companies, which began in 2022 to develop and commercialize SK Biopharmaceuticals’ anti-seizure medication cenobamate (sold as XCOPRI® in the U.S.). Hassan Kotob, former CEO of Brain Scientific, has been appointed CEO of Mentis Care. A seasoned executive with a track record in high-growth health technology companies, Kotob will lead the development of a first-of-its-kind predictive platform for brain health, aiming to transform how seizures and other neurological events are managed. Kotob stated, “Mentis Care is on a mission to help people with epilepsy live safer, more independent lives through AI-driven seizure prediction and monitoring. By combining the innovation strengths of SK Biopharmaceuticals and Eurofarma, we are setting a new global standard in digital epilepsy care.” Rodrigo Pereira, Global Executive Director of Entrepreneurship and Digital at Eurofarma, said the joint venture represents a forward-looking vision for healthcare, merging digital innovation with pharmaceuticals to deliver meaningful improvements in patient outcomes. He highlighted Eurofarma’s long-standing leadership in CNS treatments in Latin America and its recent investments in digital R&D. Donghoon Lee, CEO of SK Biopharmaceuticals, emphasized the company’s shift toward patient-centered innovation, saying, “Through Mentis Care, we are expanding our impact beyond drug development to create holistic solutions that improve the lives of people with epilepsy through AI and data integration.” Mentis Care is positioned to address a major unmet need: nearly 40% of epilepsy patients do not achieve seizure freedom despite available treatments. With epilepsy affecting approximately 3.4 million people in the U.S. alone and 150,000 new cases diagnosed annually, the demand for advanced monitoring and predictive tools is growing rapidly. The joint venture underscores a broader trend in healthcare—integrating AI and digital technologies with pharmaceuticals to deliver smarter, more proactive care.